TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged between 18 and 35 years, nonsmokers~* Body mass index between 15th and 85th percentile~* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant~* Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant~* Normal ophthalmic findings, ametropia \< 3 Dpt~Exclusion Criteria:~* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study~* Treatment in the previous 3 weeks with any drug, vitamins and minerals supplements as well~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* History of hypersensitivity to the trial drug or to drugs with a similar chemical structure~* History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with, distribution, metabolism or excretion of study drugs~* Blood donation during the previous 3 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olmesartan Medoxomil in Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus type 2, defined as fasting blood glucose of greater than or equal to 126 mg/dL;~* Presence of at least one of the following cardiovascular risk factors:~  1. total cholesterol greater than 200 mg/dL or statin treatment,~ 2. High density lipoprotein (HDL) less than 40 mg/dL,~ 3. triglycerides greater than 150 mg/dL and less than 400 mg/dL,~ 4. blood pressure greater than or equal to 130/80 mmHg,~ 5. Body mass index (BMI) greater than 28 kg/m2,~ 6. waist circumference greater than 102 cm for men and greater than 88 cm for women,~ 7. smoking of more than 5 cigarettes a day;~* Normoalbuminuria at screening~Exclusion Criteria:~* Severe uncontrolled hyperlipidemia;~* Documented renal and/or renal-vascular disease;~* Myocardial infarction, stroke or myocardial revascularization within the last 6 months;~* History of alcohol and/or drug abuse;~* Allergic reaction, lack of response or contraindication to angiotensin receptor blockers (ARBs);~* Current treatment with an ARB or angiotensin converting enzyme (ACE) inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): olmesartan medoxomil
- 2 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Acute Sinusitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in accordance with the local production information.~Exclusion Criteria:~* Those specified in the local product information - contraindications and precautions must be considered.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Individuals ≥ 40 kg in weight with chronic genotype 1 or 2 HCV and HBV coinfection~* Individuals must not be taking or requiring treatment with HBV antiviral therapy at screening. For participants that are HBV treatment experienced, the most recent treatment must have been completed at least 6 months prior to Day 1.~* Cirrhosis determination by Fibroscan~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female or male is of childbearing potential~Key Exclusion Criteria:~* Current or prior history of clinically-significant illness or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~* Pregnant or nursing female~* Infection with human immunodeficiency virus (HIV) or hepatitis delta virus (HDV)~* Hepatocellular carcinoma (HCC) or other malignancy~* Current or prior history of clinical hepatic decompensation~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (Type: EXPERIMENTAL): LDV/SOF FDC for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OsteoCool Tumor Ablation Post-Market Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Candidate for OsteoCool RF ablation per the labeled indication applicable in their respective country/region~2. A. Metastatic lesions targeted for treatment must be located in the thoracic and/or lumbar vertebral body(ies), periacetabulum, iliac crest, and/or sacrum OR benign bone tumors - no restrictions on location of lesion~3. Report worst pain score ≥4/10 at the target treatment site within the past 24 hours~4. Localized pain resulting from no more than two sites total of metastatic disease~5. Have Karnofsky score ≥40 at enrollment (not applicable for subjects with benign bone tumors)~6. Willing and able to provide a signed and dated informed consent, comply with the study plan, follow up visits and phone calls~7. At least 18 years old at the time of informed consent~Exclusion Criteria:~1. A. Implanted with heart pacemaker or other implanted electronic device (Europe and Canada only)~2. Use of OsteoCool in vertebral body levels C1-C7~3. Multiple myeloma, solitary plasmacytoma, or primary malignant lesions in the index vertebra or bone~4. Active or incompletely treated local infection at the planned treatment site(s) and/or systemic infection~5. Planned treatment site(s) accompanied by objective evidence of secondary radiculopathy or neurologic compromise~6. Planned treatment site(s) associated with spinal cord compression or canal compromise requiring decompression~7. Fractures due to prostatic cancer or other osteoblastic metastases to the spine. Metastatic lesions originating in the prostate that are osteolytic or mixed origin are eligible for the study~8. Pregnant, breastfeeding, or plan to become pregnant during the study duration~9. Concurrent participation in another clinical study that may add additional safety risks and/or confound study results\*~10. Any condition that would interfere with the subject's ability to comply with study instructions or might confound the study interpretation~    * Subjects in concurrent studies can only be enrolled with permission from Medtronic. Please contact Medtronic's study manager to determine if the subject can be enrolled in both studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OsteoCool™ RF Ablation (Type: OTHER): Subjects will undergo a single OsteoCool™ RF Ablation procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Comparisons of Two Donepezil Formulations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males age 20 to 45 years~* Body weight \> 45 kg with +/- 20% of ideal body weight~* Signed and dated informed consent form which meets all criteria of current FDA and KFDA regulations~Exclusion Criteria:~* subjects with acute conditions.~* presence of history affecting ADME~* Clinically significant history or current evidence of a hepatic, renal, gastrointestinal, or hematologic abnormality~* Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings~* Any other acute or chronic disease~* A history of hypersensitivity to donepezil~* A history of alcohol or drug abuse~* Participation in another clinical trial within 3 months~* smoked \>10 cigarettes daily~* consumption over 5 glasses daily of beverages containing xanthine derivatives~* use of any medication having the potential to affect the study results within 10 days before the start of the study.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Reference arm (Type: ACTIVE_COMPARATOR): Treated with Reference (Aricept, 10 mg donepezil tablet)
- Test arm (Type: EXPERIMENTAL): Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic breast cancer confirmed by biopsy~* Prior adjuvant/neoadjuvant treatment allowed~* Measurable disease~* Able to perform activities of daily living with minimal assistance~* Age 18 years or older~* Adequate bone marrow, liver and kidney function~* Normal heart function~* Written informed consent~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Pre-existing moderate peripheral neuropathy~* History of significant heart disease~* Meningeal metastases.~* Prior chemotherapy for metastatic breast cancer~* No measurable disease (including bone only, pleural effusions, etc.)~* Receiving Herceptin therapy.~* Women who are pregnant or lactating.~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Doxorubicin (Type: EXPERIMENTAL): Liposomal doxorubicin 40 mg/m2 by 1 hour IV infusion repeated every 28 days.
- Docetaxel (Type: EXPERIMENTAL): Weekly docetaxel 36 mg/m2 by 30 minute IV infusion on days 1, 8, and 15 of the 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Insulin Therapy With Enhanced Care Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* HbA1c \> 7%~* age \> 21~Exclusion Criteria:~* substance abuse disorder~* serious psychiatric illness~* serious hearing loss~* life expectancy \< 12 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reciprocal Diabetes Peer Support program (Type: EXPERIMENTAL): peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
- Nurse Case Management (Type: OTHER): patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of FYU-981 in Hyperuricemia With or Without Gout

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemic or gout patients~* Serum urate level:~\>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL~Exclusion Criteria:~* Gouty arthritis within two weeks before start of study treatment~* Secondary hyperuricemia~* HbA1c: \>= 8.4%~* Uric acid-overproduction type in the classification of hyperuricemia~* History of, clinically significant cardiac, hematologic and hepatic disease~* Kidney calculi or clinically significant urinary calculi~* eGFR: \< 30mL/min/1.73m\^2~* Systolic blood pressure: \>= 180 mmHg~* Diastolic blood pressure: \>= 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FYU-981 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Histologically confirmed metastatic melanoma (AJCC stage IV) or unresectable melanoma (AJCC Stage III)~* Prior failure of \>/= 1 prior treatment regimens for metastatic or unresectable melanoma due to disease progression or unacceptable toxicity and for whom no standard therapy is available~* Measurable disease according to RECIST criteria~* Adequate bone marrow, liver and renal function~* Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception through the course of the study treatment and for 6 months after the last dose of study treatment~Exclusion Criteria:~* Treatment with cytotoxic or antibody based therapy within 21 days prior to first dose of study treatment, or with any other anti-cancer therapy within 5 half-lives of the therapy prior to first dose of study treatment~* Known active infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds)~* Current Grad \>/= 2 toxicity (except alopecia or anorexia) from prior therapy~* Grade \>/= 2 peripheral neuropathy~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapies (or recombinant antibody-related fusion proteins)~* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis~* Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)~* Evidence of significant uncontrolled concomitant disease or disorder~* Pregnant or lactating women~* Prior treatment with any other antibody-drug conjugate (ADC) compound containing monomethyl auristatin E (MMAE) for the treatment of melanoma~* Previous participation in a clinical trial within 30 days of the day of first study drug administration (Cycle 1, Day 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Main inclusion criteria:~1. Familial or sporadic ALS~2. Patient diagnosed with probable of definite ALS~3. Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening~Exclusion Criteria:~1. Patient who underwent tracheostomy and/or gastrostomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Masitinib (3.0) & Riluzole (Type: EXPERIMENTAL): masitinib 3 mg/kg/day + riluzole
- Masitinib (4.5) & Riluzole (Type: EXPERIMENTAL): masitinib 4.5 mg/kg/day (2) + riluzole
- Placebo & Riluzole (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet the following criteria for study entry:~* Histologically confirmed NSCLC~* Availability of a tumor specimen~* Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease~* Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)~* At least one measurable lesion on a pre-treatment 18-fluorodeoxyglcose-positron emission tomography (FDG-PET) scan that is also a target lesion on computed tomography (CT) according to RECIST~Exclusion Criteria:~* More than two prior treatments for Stage IIIB/IV~* More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known epidermal growth factor receptor (EGFR)-related toxicity resulting in dose modifications~* Chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization~* Untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (CNS) metastasis~* History of serious systemic disease within the past 6 months prior to randomization~* Uncontrolled diabetes~* Major surgical procedure or significant traumatic injury within 28 days prior to randomization~* Anticipation of need for a major surgical procedure during the course of the study~* Local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to Grade II or less prior to randomization~* Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MetMAb + Erlotinib (Type: EXPERIMENTAL): MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
- Placebo + Erlotinib (Type: PLACEBO_COMPARATOR): Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete